Tag: atrial fibrillation

1. There was no significant difference found in thrombosis or bleeding outcomes for patients with atrial fibrillation or mechanical heart valves, where patients were randomly assigned to receive dalteparin or a placebo after an invasive procedure requiring cessation of warfarin. Evidence Rating Level: 1 (Excellent) Patients with atrial fibrillation or mechanical...
1. In patients with recent ischemic stroke and no diagnosed atrial fibrillation (AF), there were increased AF diagnoses in those who received an implantable loop recorder compared with those who received an external loop recorder within 12 months of the intervention. Evidence Rating Level: 1 (Excellent) Study Rundown: Atrial fibrillation (AF)...
1. Compared to patients only receiving rate-control treatment, those who received rhythm-control treatment within one year of diagnosis of atrial fibrillation had a lower risk of adverse cardiovascular outcomes. 2. This association was not seen if the treatment was initiated over one year after the diagnosis of atrial fibrillation. Evidence Rating...
1. In patients with recent ischemic stroke and no diagnosed atrial fibrillation (AF), there were increased AF diagnoses in those who received an implantable loop recorder compared with those who received an external loop recorder within 12 months of the intervention. Evidence Rating Level: 1 (Excellent) Study Rundown: Atrial fibrillation (AF)...
1. Roughly 33.8% of patients with atrial fibrillation and/or venous thromboembolism undergoing treatment with a direct oral anticoagulant (DOAC) were also being treated with aspirin without a clear indication. 2. Patients being treated with DOAC and aspirin experienced significantly more bleeding events and hospitalizations, compared to DOAC monotherapy. Evidence Rating Level:...
1. In patients treated with direct oral anticoagulants (DOACs) for atrial fibrillation or venous thromboembolism (VTE), adding aspirin (ASA) was associated with increased bleeding events. 2. Adding ASA to DOAC treatment for patients with atrial fibrillation or VTE did not improve the incidence of thrombotic events. Evidence Rating Level: 2 (Good) Study Rundown: Aspirin...
1. Patients who received a direct oral anticoagulant had a lower risk of thromboembolic events and major bleeds compared to patients who received warfarin. 2. The between-group differences were consistent across all prespecified clinically relevant subgroups. Evidence Rating Level: 2 (Good) Study Rundown: It is recommended for patients with atrial fibrillation to...
1. Direct oral anticoagulants may have a superior risk-benefit profile compared to vitamin K antagonists in atrial fibrillation for patients with hemodialysis. Evidence Rating Level: 2 (Good) While direct oral anticoagulants (DOACs) have been shown to have superior risk-benefit profiles over vitamin K antagonists (VKAs) in patients with atrial fibrillation and normal...
1. Direct oral anticoagulants may have a superior risk-benefit profile compared to vitamin K antagonists in atrial fibrillation for patients with hemodialysis. Evidence Rating Level: 2 (Good) While direct oral anticoagulants (DOACs) have been shown to have superior risk-benefit profiles over vitamin K antagonists (VKAs) in patients with atrial fibrillation and...
1. The C2HEST score had moderate accuracy in predicting sustained atrial high-rate episodes (SAHREs) for patients with cardiac implantable electronic devices, but no atrial fibrillation. 2. A 1-point increase in the C2HEST score was associated with a 39% increased risk of SAHREs). Evidence Rating Level: 2 (Good) In patients without atrial fibrillation...